TITLE

TOP STORIES

PUB. DATE
November 2013
SOURCE
MondayMorning;11/4/2013, Vol. 21 Issue 40, p1
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
This section offers U.S. news briefs as of November 4, 2013. An apology was issued by U.S. Health Secretary Kathleen Sebelius on the malfunctions experienced by Americans enrolling on the Obamacare exchange using its web site, but the secretary remains firm on not dismissing people who worked on the web site. A "JAMA Internal Medicine"-published study revealed that fewer patients are involved in the expedited reviews of new drugs approved by the U.S. Food and Drug Administration (FDA).
ACCESSION #
91959043

 

Related Articles

  • Fighting science with politics.  // Nature Medicine;Jan2012, Vol. 18 Issue 1, p1 

    The author reflects the issue on the policy on contraceptive pills and the invovement of politics. The author cites the overruling by the U.S. Department of Health and Human Services (HHS) secretary, Kathleen Sebelius of the U.S. Food and Drug Administration's (FDA) decision that approve the...

  • FDA Accepts Neurocrine's Resubmitted Application for Insomnia Drug. Chambers, Heather // San Diego Business Journal;9/3/2007, Vol. 28 Issue 36, p10 

    The article offers news briefs in San Diego, California. A resubmitted new drug application for an insomnia treatment developed by Neurocrine Biosciences Inc. has been accepted for review by the Food and Drug Administration. Nanogen Inc. announced a $20 million registered offering of unsecured...

  • News from the FDA.  // Patient Care for the Nurse Practitioner;Sep2004, Vol. 7 Issue 9, p12 

    This section presents news briefs related to the U.S. Food and Drug Administration (FDA). Aldara was approved for the treatment of biopsy-confirmed, primary superficial basal cell carcinoma tumors with a maximum diameter of 2 cm in adults with normal immune systems when surgical methods are...

  • FDA Clears J&J, Medivir Hepatitis C Pill for Market.  // Chain Drug Review;12/16/2013, Vol. 35 Issue 20, p86 

    The article offers news briefs on the pharmaceutical industry in the U.S. including approval of the drug simeprevir by the U.S. Food and Drug Administration, plans of Horizon Pharma Inc. to buy the rights to sell the drug Vimovo in the country, and approval of Noxafil tablets by FDA.

  • NEWSLINE.  // MPR - Pharmacist's Edition;Winter2015/2016, Vol. 9 Issue 4, pA5 

    This section offers news briefs related to the pharmaceutical industry in the U.S. Topics discussed include an approval granted by the U.S. Food and Drug Administration (FDA) to Nucala for injection as add-on maintenance treatment in patients with severe asthma, and an FDA approval for Novartis'...

  • Obama Defends Limits on Morning-After Pill.  // MondayMorning;12/12/2011, Vol. 19 Issue 45, p3 

    The article reports on the decision of Kathleen Sebelius, secretary of Health and Human Services (HHS), to overrule the approval of the U.S. Food and Drug Administration (FDA) on the request of Teva Pharmaceutical Industries Ltd. to sell its emergency contraceptive pill Plan B over the counter....

  • FDA to Reschedule Hydrocodone.  // State Journal (WV);11/1/2013, Vol. 29 Issue 43, p9 

    The article reports that on an announcement by the Department of Health and Human Services Secretary Kathleen Sebelius regarding the rescheduling of hydrocodone combination drugs from a Schedule III drug to a Schedule II controlled substance by the U.S. Food and Drug Administration.

  • As I See It. Dickinson, James G. // Medical Marketing & Media;Feb2012, Vol. 47 Issue 2, p28 

    The article presents the author's views regarding the intervention of U.S. Health and Human Services (HHS) Secretary Kathleen Sebelius to the decision making of the Food and Drugs Administration (FDA) about the approval of Plan B emergency contraceptive in 2012.

  • NEWSLINE.  // MPR - Pediatricians' Edition;Fall/Winter2015/2016, Vol. 26 Issue 2, pA4 

    The article offers U.S. pharmaceutical industry news briefs as of November 2015. The withdrawal of approval of a New Drug Application for Elepsia XR extended-release tablets by the U.S. Food & Drug Administration (FDA). The approval for OxyContin extended-release tablets for pediatric patients...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics